Just what's in the PR's. Today https://www.ipharminc.com/press-release/2018/3/15/innovation-pharmaceuticals-views-brilacidin-om-as-clearly-differentiated-compared-to-limited-competition-for-preventing-severe-oral-mucositis secondary https://www.ipharminc.com/press-release/2018/1/3/innovation-pharmaceuticals-brilacidin-meets-key-secondary-endpoint-in-phase-2-trial-delays-onset-of-severe-oral-mucositis-som primary(topline) https://www.ipharminc.com/press-release/2017/12/11/innovation-pharmaceuticals-reports-positive-topline-results-from-phase-2-placebo-controlled-trial-of-brilacidin-for-the-prevention-of-oral-mucositis-in-head-and-neck-cancer-patients I